Endo Pharmaceuticals Receives FDA Approval for Felodipine Extended-Release Tablets USP, 2.5mg, 5mg and 10mg
CHADDS FORD, Pa., Nov. 2, 2011 /PRNewswire/ — Endo Pharmaceuticals (Nasdaq: ENDP) today announced that the U.S. Food and Drug Administration has approved Felodipine Extended-release Tablets USP, 2.5mg, 5mg and 10mg. Qualitest Pharmaceuticals, the generic business unit of Endo Pharmaceuticals, will manufacture and distribute the Felodipine Extended-release Tablets.
Felodipine Extended-release Tablets USP are the generic version of AstraZeneca’s PlendilÃ‚® Extended-release Tablets.
The total sales for Felodipine in the U.S. for the 12 months ended June 30, 2011 were approximately $84 million, according to IMS Health.
Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments – branded pharmaceuticals, generics and devices and services. We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit http://www.endo.com/.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “intend,” “guidance,” “future” or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
SOURCE Endo Pharmaceuticals